You should remember that it was NP who brought pro-140 back from the brink of being shelved and forgotten. He is the one who wanted to try the higher dose and continue looking for other indications. Yes, it has taken longer than expected and the stock price doesn’t reflect true value, but delays and financing are a part of every fledgling biotech out there. Go to another biotech board and the same conversations are happening: financing, CEO salary, OTC holding the company back, etc. The biggest difference here is the science, proven in a phase 3, with little side effects and across multiple indications with very large markets. CYDY will be worth we’ll above what the stock price is today, but it won’t be a smooth path to that price. More dilution is on the way before a licensing deal is made.
Market Data 
Markets 
AI
